Stifel Downgrades Crinetics (CRNX) to Hold

Evercore ISI Downgrades Crinetics (CRNX) to In Line

Evercore ISI analyst Gavin Clark-Gartner downgraded Crinetics (NASDAQ: CRNX) from Outperform to In Line with a price target of $85.00 (from $88.00).

For an analyst ratings summary and ratings history on Crinetics click here. For more ratings news on Crinetics click here.

Shares of Crinetics closed at $83.53 yesterday.

TD Cowen Downgrades Crinetics (CRNX) to Hold

TD Cowen analyst Tyler Van Buren downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold.

For an analyst ratings summary and ratings history on Crinetics click here. For more ratings news on Crinetics click here.

Shares of Crinetics closed at $42.03 yesterday.

Citizens Downgrades Crinetics (CRNX) to Market Perform

Citizens analyst Jonathan Wolleben downgraded Crinetics (NASDAQ: CRNX) from Market Outperform to Market Perform.

For an analyst ratings summary and ratings history on Crinetics click here. For more ratings news on Crinetics click here.

Shares of Crinetics closed at $42.03 yesterday.

Jefferies Downgrades Crinetics (CRNX) to Hold

Jefferies analyst Dennis Ding downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold.

For an analyst ratings summary and ratings history on Crinetics click here. For more ratings news on Crinetics click here.

Shares of Crinetics closed at $42.03 yesterday.

Jones Trading Downgrades Crinetics (CRNX) to Hold

Jones Trading analyst Catherine Novack downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold.

The analyst comments "What's new: Vertex (VRTX, Not Rated) announced an agreement to acquire Crinetics for $85/share in cash, implying an equity valuation of ~$10B or $8.8B net of estimated... More

Piper Sandler Downgrades Crinetics (CRNX) to Neutral

Piper Sandler analyst Yasmeen Rahimi downgraded Crinetics (NASDAQ: CRNX) from Overweight to Neutral.

For an analyst ratings summary and ratings history on Crinetics click here. For more ratings news on Crinetics click here.

Shares of Crinetics closed at $42.03 yesterday.

H.C. Wainwright Downgrades Crinetics (CRNX) to Neutral

H.C. Wainwright analyst Douglas Tsao downgraded Crinetics (NASDAQ: CRNX) from Buy to Neutral.

For an analyst ratings summary and ratings history on Crinetics click here. For more ratings news on Crinetics click here.

Shares of Crinetics closed at $42.03 yesterday.

Vertex (VRTX) Reiterated at Overweight by Cantor Fitzgerald; Crinetics Acquisition Announced

Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $590.00 price target on Vertex (NASDAQ: VRTX).

The analyst commented, "Vertex announced its acquisition of Crinetics (CRNX, N, Schimmer) this afternoon (07/06) for ~$10bn (deal terms below), providing the company another near-term launch narrative (Palsonify in... More

Crinetics Pharmaceuticals (CRNX) call put ratio 13.7 calls to 1 put into Vertex Pharmaceuticals Incorporated (VRTX) acquiring

Crinetics Pharmaceuticals (NASDAQ: CRNX) 30-day option implied volatility is at 66; compared to its 52-week range of 42 to 92. Call put ratio 13.7 calls to 1 put into Vertex Pharmaceuticals Incorporated (VRTX) acquiring CRNX.

Crinetics (CRNX) PT Raised to $85 at Baird

Baird analyst Brian Skorney raised the price target on Crinetics (NASDAQ: CRNX) to $85.00 (from $62.00) while maintaining a Outperform rating.... More

Oppenheimer Downgrades Crinetics (CRNX) to Perform

Oppenheimer analyst Leland Gershell downgraded Crinetics (NASDAQ: CRNX) from Outperform to Perform.

The analyst comments: VRTX (OP, Olson) will acquire CRNX for $85/share in cash as announced this evening, a 100% premium to today's closing price. The transaction is expected to close this... More

Cantor Fitzgerald Downgrades Crinetics (CRNX) to Neutral

Cantor Fitzgerald analyst Josh Schimmer downgraded Crinetics (NASDAQ: CRNX) from Overweight to Neutral.

The analyst comments: This afternoon's announcement that VRTX (OW, Carter) is acquiring CRNX came as a big surprise - mostly due to the timing of the deal. The $10B acquisition marks the 4th $10B+ M&A deal of 2026 for biopharma - tying the record... More

Crinetics soars on $10B acquisition by Vertex

Investing.com -- Vertex Pharmaceuticals Incorporated announced Monday it will acquire Crinetics Pharmaceuticals, Inc. for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired.

Crinetics shares surged over 100% following the announcement. Vertex shares traded 0.5% lower.

The boards of directors of both companies approved the transaction unanimously. The deal is expected to close in the third quarter of 2026, subject to customary closing conditions, including... More

Vertex to acquire Crinetics Pharmaceuticals for $10 billion

Vertex Pharmaceuticals (NASDAQ: VRTX) has agreed to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or $8.8 billion net of estimated cash acquired, according to a joint press release from the companies.

Both boards of directors... More